Company intelligence / Profile preview
Crossject
Dijon, Francecrossject.com ↗
- Ownership
- Public · ALCJ
- Development stage
- NDA
01
Overview
Crossject's lead product ZEPIZURE®, a needle-free midazolam autoinjector for epileptic seizure rescue and nerve agent exposure, has completed key manufacturing milestones and stability data collection. The company expects to file an Emergency Use Authorization with the FDA in early next year and begin U.S. commercialization soon after. A $60–92 million contract with BARDA supports U.S. government procurement upon approval. Other pipeline products are advancing through clinical and regulatory stages targeting emergency indications such as adrenal crisis, anaphylaxis, opioid overdose, and asthma attacks.
- Therapeutic areas
- ImmunologyNeurologyEndocrinology
- Modalities
- Small molecules (reformulated for needle-free delivery)Complex injectables (e.g., hydrocortisone, midazolam)Supergenerics/New Therapeutic Entities using known drugs
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
BARDA/U.S. Department of Health & Human Services—contract for ZEPIZURE®Eton Pharmaceuticals—U.S./Canada rights to ZENEO Hydrocortisone programSyneos Health—commercial launch support in the U.S.
04
Financials
- Market cap
- $45.2B
- Total revenue
- $9.9B
- Enterprise value
- $45.3B
Beyond the preview
Go deeper on Crossject.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Crossject.